Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next. - ...

Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.  BioPharma Dive

Daiichi Sankyo Company, Limited's (TSE:4568) P/E Is On The Mark - simplywall.st

Daiichi Sankyo Company, Limited's (TSE:4568) P/E Is On The Mark  simplywall.st

Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings - B...

Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings  BioSpace

What we’re hearing on Chinese NewCos, AI, and BIO’s executive ranks - STAT

What we’re hearing on Chinese NewCos, AI, and BIO’s executive ranks  STAT

Daiichi Sankyo and Merck Pull Back Patritumab Deruxtecan BLA Based on Phase III HERTHENA-Lung02 O...

Daiichi Sankyo and Merck Pull Back Patritumab Deruxtecan BLA Based on Phase III HERTHENA-Lung02 Outcomes  Applied Clinical Trials

Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch' - Fierce P...

Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch'  Fierce Pharma

Daiichi Sankyo is leveraging Azure OpenAI Service to develop generative AI and foster an AI-frien...

Daiichi Sankyo is leveraging Azure OpenAI Service to develop generative AI and foster an AI-friendly culture  Microsoft

Wayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for...

Wayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for neurodegenerative disease  PR Newswire

Daiichi, Merck pull HER3-DXd filing at FDA after confirmatory trial misses survival endpoint - Fi...

Daiichi, Merck pull HER3-DXd filing at FDA after confirmatory trial misses survival endpoint  Fierce Biotech

Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Gl...

Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH  Business Wire

Daiichi Sankyo connects cherry blossom trees to future of oncology pipeline - Medical Marketing a...

Daiichi Sankyo connects cherry blossom trees to future of oncology pipeline  Medical Marketing and Media

AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy - ...

AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy  MedCity News

Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO - Pharmaceutical Technology

Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO  Pharmaceutical Technology

Straying From “the Plan”: Patricia Barbieri of Daiichi Sankyo on Journey to Success - Lowenstein ...

Straying From “the Plan”: Patricia Barbieri of Daiichi Sankyo on Journey to Success  Lowenstein Sandler LLP

AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data - BioSpace

AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data  BioSpace

Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to De...

Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines  Business Wire

Daiichi Sankyo builds $152M ADC plant in China as Enhertu wins national coverage - Fierce Pharma

Daiichi Sankyo builds $152M ADC plant in China as Enhertu wins national coverage  Fierce Pharma

Daiichi Sankyo Admits 2024 Wasn’t ‘Perfect’ but 2025 Is Starting Off With a Bang - BioSpace

Daiichi Sankyo Admits 2024 Wasn’t ‘Perfect’ but 2025 Is Starting Off With a Bang  BioSpace

Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer - Business Wire

Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer  Business Wire

Daiichi Sankyo celebrates its roots and blooming future at DC cherry blossom festival - Fierce Ph...

Daiichi Sankyo celebrates its roots and blooming future at DC cherry blossom festival  Fierce Pharma

Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo - Pharmaceutical Technology

Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo  Pharmaceutical Technology

AstraZeneca, Daiichi Sankyo's Enhertu rings up success in another breast cancer trial - Fierce Ph...

AstraZeneca, Daiichi Sankyo's Enhertu rings up success in another breast cancer trial  Fierce Pharma

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC - OncLive

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC  OncLive

Daiichi Sankyo and Merck withdraw BLA for patritumab deruxtecan in US - World Pharmaceutical Fron...

Daiichi Sankyo and Merck withdraw BLA for patritumab deruxtecan in US  World Pharmaceutical Frontiers

At ASCO 2025, attendees see reason for hope, despite worries - STAT

At ASCO 2025, attendees see reason for hope, despite worries  STAT

Daiichi Sankyo exec on purposeful data collection - Clinical Trials Arena

Daiichi Sankyo exec on purposeful data collection  Clinical Trials Arena

Milestone launch for Daiichi Sankyo’s Datroway in Japan - The Pharma Letter

Milestone launch for Daiichi Sankyo’s Datroway in Japan  The Pharma Letter

Daiichi Sankyo CEO Hiroyuki Okuzawa to Lead Expansion of ADC Portfolio Including Enhertu and Datr...

Daiichi Sankyo CEO Hiroyuki Okuzawa to Lead Expansion of ADC Portfolio Including Enhertu and Datroway  geneonline.com

Exclusive: Daiichi Sankyo, Johnson & Johnson partner with RNA delivery startup Nosis Bio - Endpoi...

Exclusive: Daiichi Sankyo, Johnson & Johnson partner with RNA delivery startup Nosis Bio  Endpoints News

Fortis Open Offer: Daiichi Sankyo's 'misleading' statements continue to damage interests, says NT...

Fortis Open Offer: Daiichi Sankyo's 'misleading' statements continue to damage interests, says NTK  The Economic Times

AstraZeneca, Daiichi Sankyo Continue ADC Rally With Enhertu Expansion - BioSpace

AstraZeneca, Daiichi Sankyo Continue ADC Rally With Enhertu Expansion  BioSpace

Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo - BioSpace

Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo  BioSpace

Daiichi Sankyo links up with Korea's Alteogen on subcutaneous Enhertu in $300M licensing deal - F...

Daiichi Sankyo links up with Korea's Alteogen on subcutaneous Enhertu in $300M licensing deal  Fierce Pharma

Daiichi Sankyo Announces New CEO - PharmExec

Daiichi Sankyo Announces New CEO  PharmExec

Daiichi Sankyo pays $132 million for Glycotope’s gatipotuzumab - The Pharma Letter

Daiichi Sankyo pays $132 million for Glycotope’s gatipotuzumab  The Pharma Letter

Daiichi Sankyo Company, Limited Just Beat Earnings Expectations: Here's What Analysts Think Will ...

Daiichi Sankyo Company, Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next  simplywall.st

Daiichi Sankyo to promote Okuzawa to CEO - biocentury.com

Daiichi Sankyo to promote Okuzawa to CEO  biocentury.com

AstraZeneca, Daiichi Sankyo ADC Lands FDA Approval in Advanced Breast Cancer - MedCity News

AstraZeneca, Daiichi Sankyo ADC Lands FDA Approval in Advanced Breast Cancer  MedCity News

Daiichi Sankyo doses first subject in Phase III AML therapy trial - Clinical Trials Arena

Daiichi Sankyo doses first subject in Phase III AML therapy trial  Clinical Trials Arena

Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m - Pharmaceutical Technology

Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m  Pharmaceutical Technology

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Bro...

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients  Yahoo Finance

Daiichi Sankyo celebrates its historic connection to the National Cherry Blossom Festival - WJLA

Daiichi Sankyo celebrates its historic connection to the National Cherry Blossom Festival  WJLA

After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period - BioSpace

After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period  BioSpace

Is Daiichi Sankyo Company (TSE:4568) Using Too Much Debt? - simplywall.st

Is Daiichi Sankyo Company (TSE:4568) Using Too Much Debt?  simplywall.st

Merck and Daiichi Sankyo Withdraw FDA Application for HER3-Targeting Lung Cancer Drug After Trial...

Merck and Daiichi Sankyo Withdraw FDA Application for HER3-Targeting Lung Cancer Drug After Trial Failures  geneonline.com

AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win - BioSpace

AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win  BioSpace

Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-...

Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO  Yahoo Finance

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer - PM...

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer  PMLiVE

MSD and Daiichi Sankyo pull HER3-DXd's FDA filing - Pharmaphorum

MSD and Daiichi Sankyo pull HER3-DXd's FDA filing  Pharmaphorum

Daiichi Sankyo and MSD Withdraw U.S. Application for Patritumab Deruxtecan in NSCLC Treatment - g...

Daiichi Sankyo and MSD Withdraw U.S. Application for Patritumab Deruxtecan in NSCLC Treatment  geneonline.com

Daiichi Sankyo Highlights Progress Across Oncology Portfolio in Multiple Solid and Blood Cancers ...

Daiichi Sankyo Highlights Progress Across Oncology Portfolio in Multiple Solid and Blood Cancers at ESMO Asia, SABCS and ASH  Business Wire

AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer - PM...

AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer  PMLiVE

While shareholders of Daiichi Sankyo Company (TSE:4568) are in the red over the last year, underl...

While shareholders of Daiichi Sankyo Company (TSE:4568) are in the red over the last year, underlying earnings have actually grown  simplywall.st

Daiichi Sankyo Joins LabCentral Community as Platinum Sponsor - PR Newswire

Daiichi Sankyo Joins LabCentral Community as Platinum Sponsor  PR Newswire

Daiichi Sankyo - drugdiscoverytrends.com

Daiichi Sankyo  drugdiscoverytrends.com

Daiichi Sankyo gins up antibody research project with German research institute - Fierce Biotech

Daiichi Sankyo gins up antibody research project with German research institute  Fierce Biotech

AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data - BioSpace

AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data  BioSpace

Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment - Pharmaceutical Technology

Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment  Pharmaceutical Technology

Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial - Yahoo Finance

Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial  Yahoo Finance

Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu - PMLiVE

Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu  PMLiVE

AstraZeneca, Daiichi Sankyo win first U.S. approval for key cancer drug - STAT

AstraZeneca, Daiichi Sankyo win first U.S. approval for key cancer drug  STAT

NTK Raises Damages Claim Against Daiichi Sankyo To A Whopping 184 Billion Yen - Finimize

NTK Raises Damages Claim Against Daiichi Sankyo To A Whopping 184 Billion Yen  Finimize

AstraZeneca and Daiichi Sankyo report data from Phase III breast cancer trial - Clinical Trials A...

AstraZeneca and Daiichi Sankyo report data from Phase III breast cancer trial  Clinical Trials Arena

Daiichi Sankyo names chief operating officer Sunao Manabe as new CEO - FirstWord Pharma

Daiichi Sankyo names chief operating officer Sunao Manabe as new CEO  FirstWord Pharma

Sankyo Co. Announces Share Repurchase Strategy - TipRanks

Sankyo Co. Announces Share Repurchase Strategy  TipRanks

Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial - Reuters

Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial  Reuters

Daiichi Sankyo appoints Hiroyuki Okuzawa as CEO - The Pharma Letter

Daiichi Sankyo appoints Hiroyuki Okuzawa as CEO  The Pharma Letter

Daiichi Sankyo: Good Diversification Tool For U.S. Investors - Seeking Alpha

Daiichi Sankyo: Good Diversification Tool For U.S. Investors  Seeking Alpha

Daiichi Sankyo Earnings: Guidance for 2025 Implies 12% Growth in Core Operating Profit - Morningstar

Daiichi Sankyo Earnings: Guidance for 2025 Implies 12% Growth in Core Operating Profit  Morningstar

Daiichi Sankyo, AstraZeneca Announce Promising DATROWAY Combination Data in NSCLC - Insider Monkey

Daiichi Sankyo, AstraZeneca Announce Promising DATROWAY Combination Data in NSCLC  Insider Monkey

AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer - PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer  PMLiVE

Daiichi Sankyo's World-Leading Antibody Drug Conjugate Platform Continues to Make Progress - Morn...

Daiichi Sankyo's World-Leading Antibody Drug Conjugate Platform Continues to Make Progress  Morningstar

AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 20...

AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024  BioSpace

Daiichi Sankyo stock jumps on strong earnings and buyback plan - Investing.com

Daiichi Sankyo stock jumps on strong earnings and buyback plan  Investing.com

AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug - STAT

AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug  STAT

AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment - Pharmaceutical Te...

AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment  Pharmaceutical Technology

AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer - PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer  PMLiVE

Daiichi Sankyo posts positive DS-9606 clinical trial results in solid tumours - Clinical Trials A...

Daiichi Sankyo posts positive DS-9606 clinical trial results in solid tumours  Clinical Trials Arena

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA approval in breast cancer - PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA approval in breast cancer  PMLiVE

Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trial - Clinical Trials ...

Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trial  Clinical Trials Arena

First global approval for Daiichi Sankyo's Dato-DXd - Pharmaphorum

First global approval for Daiichi Sankyo's Dato-DXd  Pharmaphorum

Company Profile: Daiichi Sankyo - Pharmaphorum

Company Profile: Daiichi Sankyo  Pharmaphorum

Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time - Pharmaceutical Tec...

Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time  Pharmaceutical Technology

Daiichi Sankyo Earnings: Results in Line, Enhertu Momentum Continues; Shares Undervalued - Mornin...

Daiichi Sankyo Earnings: Results in Line, Enhertu Momentum Continues; Shares Undervalued  Morningstar

BioMed X Launches Collaboration with Daiichi Sankyo to Explore New Approaches in Cancer Treatment...

BioMed X Launches Collaboration with Daiichi Sankyo to Explore New Approaches in Cancer Treatment  Contract Pharma

AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe - PMLiVE

AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe  PMLiVE

Daiichi Sankyo rises on share buyback plan - Seeking Alpha

Daiichi Sankyo rises on share buyback plan  Seeking Alpha

Dato-DXd has sufficient potential as an ADC succeeding Enhertu: Daiichi Sankyo - koreabiomed.com

Dato-DXd has sufficient potential as an ADC succeeding Enhertu: Daiichi Sankyo  koreabiomed.com

A next-generation form of chemotherapy wins FDA approval - STAT

A next-generation form of chemotherapy wins FDA approval  STAT

AstraZeneca & Daiichi Sankyo’s Enhertu Approved by FDA for Treatment of Metastatic Breast Cancer ...

AstraZeneca & Daiichi Sankyo’s Enhertu Approved by FDA for Treatment of Metastatic Breast Cancer  Contract Pharma

Daiichi Sankyo’s Markus Kosch on Equitable Access to Medicine - themedicinemaker.com

Daiichi Sankyo’s Markus Kosch on Equitable Access to Medicine  themedicinemaker.com

Daiichi Sankyo: Will Boost ADC Cancer Drug Production - Bloomberg

Daiichi Sankyo: Will Boost ADC Cancer Drug Production  Bloomberg

Inside ASCO 2025: Big data drops and a towering campaign - Fierce Pharma

Inside ASCO 2025: Big data drops and a towering campaign  Fierce Pharma

Daiichi Sankyo taps new CEO, aims to build up ADC franchise - Endpoints News

Daiichi Sankyo taps new CEO, aims to build up ADC franchise  Endpoints News

AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer - Managed Healthcare Ex...

AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer  Managed Healthcare Executive

AstraZeneca, Daiichi Sankyo’s ADC Flops in Phase III Breast Cancer on Heels of Lung Cancer Stumbl...

AstraZeneca, Daiichi Sankyo’s ADC Flops in Phase III Breast Cancer on Heels of Lung Cancer Stumble  BioSpace

Daiichi Sankyo aims to launch 5 ADC therapies in Korea by 2030 - koreabiomed.com

Daiichi Sankyo aims to launch 5 ADC therapies in Korea by 2030  koreabiomed.com

Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment t...

Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease  Business Wire

Daiichi Sankyo Rises Most in Five Months on Cancer Drug Approval - Bloomberg

Daiichi Sankyo Rises Most in Five Months on Cancer Drug Approval  Bloomberg

Sankyo Co 6417 FY Net Y53.99B Vs Net Y53.79B - MarketWatch

Sankyo Co 6417 FY Net Y53.99B Vs Net Y53.79B  MarketWatch